Completed PHASE2/PHASE3 INTERVENTIONAL 2-arm NCT01621321

Voriconazole Versus Oral Steroids in Allergic Bronchopulmonary Aspergillosis

A Randomized Controlled Trial of Voriconazole in Allergic Bronchopulmonary Aspergillosis

Sponsor: Cipla Ltd.

Conditions Allergic Bronchopulmonary Aspergillosis

Updated 7 times since 2017 Last updated: Dec 11, 2017 Started: Jun 30, 2013 Primary completion: Apr 30, 2016 Completion: Apr 30, 2016

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE2/PHASE3 clinical study on Allergic Bronchopulmonary Aspergillosis, this trial is completed. The trial is conducted by Cipla Ltd. and has accumulated 7 data snapshots since 2013. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

7 versions recorded

Jul 2025 — Present [monthly]

Completed PHASE2/PHASE3
Sep 2024 — Jul 2025 [monthly]

Completed PHASE2/PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2/PHASE3

Phase: PHASE2_PHASE3 → PHASE2/PHASE3
Apr 2024 — Jul 2024 [monthly]

Completed PHASE2_PHASE3
Jan 2021 — Apr 2024 [monthly]

Completed PHASE2_PHASE3

▶ Show 2 earlier versions

Jun 2018 — Jan 2021 [monthly]

Completed PHASE2_PHASE3
Jan 2017 — Jun 2018 [monthly]

Completed PHASE2_PHASE3

First recorded

Jun 2013

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Cipla Ltd.
Post Graduate Institute of Medical Education and Research, Chandigarh

Data source: Post Graduate Institute of Medical Education and Research, Chandigarh

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Chandigarh, India